-
Syntrix Receives $2.965M Grant to Conduct a Phase Ib Clinical Trial Investigating Omnitram for the Treatment of Pain in Patients Resistant to Tramadol
-Syntrix announced today the award of a $2.965 million grant from the National Institute on Drug Abuse (NIDA) of the…
3 -
Syntrix Receives $1.725M Grant to Conduct a Phase II Clinical Trial Investigating Omnitram for the treatment of Diabetic Neuropathic Pain
-Syntrix announced today the award of a $1.725 million grant from the National Institute on Drug Abuse (NIDA) of the National Institutes of Health (NIH) to perform a clinical study investigating the
Posts tagged with ‘NIDA’
Syntrix Pharmaceuticals > NIDA